Assignee
NKARTA INC
US·6 granted patents·16 pending applications·32 citations·filing 2019–2025
Top patents by PatentIndex Score
22 records- 0194US11253547B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Feb 22, 2022·11 cites·19 claims
- 0294US11154575B2Cancer immunotherapy using CD19-directed chimeric antigen receptorsNKARTA INC·Filed 2020·Granted Oct 26, 2021·10 cites·25 claims
- 0394US11141436B2Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Oct 12, 2021·8 cites·16 claims
- 0489US12398187B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2022·Granted Aug 26, 2025·1 cites·24 claims
- 0588US12012458B2Genetically modified natural killer cells for CD70-directed cancer immunotherapyNKARTA INC·Filed 2021·Granted Jun 18, 2024·2 cites·26 claims
- 0675US2025296970A1Cd19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2025·Application pending·0 cites
- 0773US2026069530A1Methods of treating primary liver tumors with natural killer cells expressing a cytotoxic receptor complexNKARTA INC·Filed 2025·Application pending·0 cites
- 0871US2024360234A1Genetically modified natural killer cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2024·Application pending·0 cites
- 0963US2024358758A1Methods for treatment of autoimmune diseasesNKARTA INC·Filed 2024·Application pending·0 cites
- 1061US2025339528A1Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cellsNKARTA INC·Filed 2022·Application pending·0 cites
- 1160US2026053925A1Dosing regimens for cd19-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1259US2023390392A1Multiplex gene edited cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1357US2025319185A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2022·Application pending·0 cites
- 1457US2026000761A1Engineered immune cells with enhanced potency and uses of same in immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1557US2021338727A1Natural killer cell compositions and immunotherapy methods for treating tumorsNKARTA INC·Filed 2019·Application pending·0 cites
- 1654US2025073266A1Dosing regimens for cancer immunotherapyNKARTA INC·Filed 2022·Application pending·0 cites
- 1754US2022411754A1Methods and compositions for enhanced expansion and cytotoxicity of natural killer cellsNKARTA INC·Filed 2020·Application pending·0 cites
- 1852US2024335536A1Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapyNKARTA INC·Filed 2021·Application pending·0 cites
- 1950US2023265390A1Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereofNKARTA INC·Filed 2021·Application pending·0 cites
- 2049US2023028399A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2021·Application pending·0 cites
- 2146US2022233593A1Combinations of engineered natural killer cells and engineered t cells for immunotherapyNKARTA INC·Filed 2020·Application pending·0 cites
- 2240US12590148B2Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapyNKARTA INC·Filed 2019·Granted Mar 31, 2026·0 cites·22 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →